variant pharmaceuticals inc variant pharmaceuticals inc restoring health transforming lives through innovation variant is committed to improving health outcomes and quality of life for patients with rare diseases learn more restoring health transforming lives through innovation variant is committed to improving health outcomes and quality of life for patients with rare diseases learn more about variant is a specialty pharmaceutical company that leverages advanced proprietary technologies to develop and commercialize bestinclass prescription drugs to help restore health and improve quality of life for patients with rare diseases learn more management at variant we leverage the expertise and passion of our team along with advanced proprietary technologies to develop and commercialize bestinclass drugs for patients while building value for our shareholders variant management board of directors  variant pharmaceuticals inc variant pharmaceuticals inc restoring health transforming lives through innovation home about about board of directors shawn m titcomb cofounder and chairman mr titcomb is cofounder and managing partner of allele capital partners a life sciences and healthcare it focused advisory and merchant banking firm previously he served as the head of investment and merchant banking at noble life science partners a division of noble capital markets prior to noble he was a founding partner at variant research corporation and senior vice president of avalon research group both of which focused on long and short life sciences equity research mr titcomb is highly proficient in scientific and corporate due diligence with the ability to leverage proprietary relationships with key opinion leaders kols and clevel life sciences executives he has a proven trackrecord of creating and identifying emerging life sciences companies with successful management teams milestone outcomes and investment returns in addition to serving as variants chairman mr titcomb also serves as an advisor to palm beach countys business development board for life sciences and as cochair for the life sciences executive council of south florida stephen c glover cofounder and chief executive officer mr glover has over  years of business experience in biopharmaceuticals and life sciences mr glover is formally the cofounder of coherus biosciences where he was focused on the business strategy partnerships product development efforts and capitalization of the company prior to coherus he was the president of insmed therapeutic proteins as well as chief business officer of insmed incorporated at insmed mr glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to merck as chief business officer he led insmeds strategic review process which resulted in the merger of insmed and transave prior to insmed mr glover held the position of senior vice president and general manager at andrx laboratories and andrx therapeutics both divisions of andrx corporation at andrx mr glover was responsible for the strategy and operation of the andrx labs which developed and marketed products in metabolic diseases and mens health and andrx therapeutics which was focused on the development of new controlled release products and contract manufacturing he earlier held multiple sales marketing and operational roles at hoffman laroche amgen inc and ims health mr glover has multifaceted experience in fortune  start up and entrepreneurial environments his transaction experience covers over  transactions totaling over  billion aaron greenblatt pharm d chief executive officer gw laboratories inc mr greenblatt has been the chief executive officer of gw laboratories inc since march   mr greenblatt previously served as chief commercial officer and executive vice president at gw laboratories inc mr greenblatt rotated through several departments in gw during various summer internships throughout high school and college and joined gw fulltime in  as the head of supply chain after building the newly formed supply chain department at gw mr greenblatt also ran the packaging department before becoming director of sales business development and company culture then as chief commercial officer mr greenblatt was the architect and chief negotiator of gw’s first and second acquisitions tripling its manufacturing footprint and employee base in a twelve month period mr greenblatt also focused on deepening customer relationships and ensuring that gw attracts and retains employees who are aligned with its core values as the fourth generation ceo from the greenblatt family mr greenblatt continues to focus on instilling the core values into the company culture talentrecruitment and development commercial partnerships and new product acquisitions in order to further increase the company’s growth trajectory and continue to build a sustainable organization jules a müsing pharmaceutical executive  advisor in the course of his career in the pharmaceutical and biotechnology industry mainly at johnson  johnson nyse jnj jules a müsing has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology prescription products and technologies and the establishment of corporate strategic alliances in this position he negotiated signed and implemented several multimillion dollar deals with small medium and large pharmaceutical and biotechnology companies on a worldwide basis he has more than  years’ experience in the pharmaceutical and biotechnology industry and has been chief executive officer president and managing director of johnson  johnson companies in the us and in europe and of the swissbased company ares serono in the us he also has been executive vice president of all ares serono companies in north and latin america additional accomplishments relate to his business development activities in se asia where he was instrumental in the establishment of johnson  johnson pharmaceutical subsidiaries in japan australia south africa thailand and other se asian countries and to his role of vice president marketing international for the janssen group of companies worldwide mr müsing currently serves as a member of the board of directors of therapeuticsmd inc and of delphi digital inc and is a member of the scientific advisory board of noble financial capital markets an investment banking and merchant banking boutique in boca raton florida mr müsing previously served as a member of the board of directors of johnson  johnson companies in germany france italy and the uk and served as a member of the management board of ortho biotech a johnson  johnson biotechnology company in the us and in europe he also served as executive chairman of pelican therapeutics inc and as a member of the board of directors of ibio inc jules a müsing received his postgraduate degree of master in sciences from the university of brussels belgium and his academic degree in economic and financial sciences  cum lauda  from the university of antwerp belgium he also completed several postgraduate courses at harvard university us and the university of cambridge uk his honors thesis on the european monetary union  was awarded with “ special recognition “ by the prime minister of belgium he has been speaker and moderator at several national and international healthcare conferences and congresses and is an advisor to a number of biotechnology and pharmaceutical companies nico p pronk director mr pronk is president and chief executive officer of noble capital markets mr pronk began his financial career in europe in  on the european options exchange eoe mr pronk has over  years’ experience working with ipos secondary offerings private placements and mergers and acquisitions during his career he has served as director or advisor to numerous privatelyheld and publicly traded companies mr pronk is a graduate of the netherlands institute of banking and finance and holds various finra licenses mr pronk is the current chairman of the board of directors of the dutch chamber of commerce in miami is a member of the board of directors of the ymca of south palm beach county foundation and is a member of the board of directors of mobilehelp about variant variant is a specialty pharmaceutical company that leverages advanced proprietary technologies to develop and commercialize bestinclass prescription drug therapies that optimize patient outcomes learn more our visionmission  variant pharmaceuticals inc variant pharmaceuticals inc restoring health transforming lives through innovation home about our visionmission about our visionmission our vision is to be recognized as a leading global specialty pharmaceutical company committed to restoring health and transforming the lives of people with rare debilitating and often life threatening conditions our mission is to develop novel bestinclass drugs that optimize health outcomes and improve quality of life for patients with rare diseases our strategy to achieve this mission is to advance development of our current product candidates commercialize our products in the united states accelerate development and maximize potential of our product candidates outside the united states through strategic alliances and collaborations with other pharmaceutical companies expand our current portfolio by leveraging our expertise in development and commercialization to identify and inlicense additional orphan drug candidates with significant commercial potential about variant variant is a specialty pharmaceutical company that leverages advanced proprietary technologies to develop and commercialize bestinclass prescription drug therapies that optimize patient outcomes learn more scientific advisory board  variant pharmaceuticals inc variant pharmaceuticals inc restoring health transforming lives through innovation home about scientific advisory board about scientific advisory board alessia fornoni md phd chief division of nephrology and hypertension director peggy and harold katz family drug discovery center university of miami miller school of medicine dr fornoni received her medical degree from the school of medicine at the university of pavia italy she subsequently obtained a phd degree in medical pharmacology at the same university she is currently tenured professor of medicine and molecular and cellular pharmacology at the university of miami miller school of medicine she is chief of the division of nephrology and hypertension and she is the director of the peggy and harold katz drug discovery center at the university of miami she is codirector of novel methods for the clinical and translational science institute ctsi and associate director of the md phd program at the same institution dr fornoni has gained experience in drug development as global head of discovery in cardiovascular and metabolism at hoffmanla roche in basel she is currently the vice president and chief scientific officer of lf health llc a small startup company focused on finding a cure for patients affected by chronic kidney diseases as a physicianscientist who has maintained a resolutely focused research program that has provided novel and seminal contributions to the understanding of the pathogenesis of kidney disease dr fornoni has conducted research supported by grants from national institutes of health industry and private foundations she has received prestigious awards serves on the editorial board of diabetes and other journals has been invited to present at national and international meetings in five different continents and has served as visiting professor at more than  academic institutions dr fornoni serves as grant reviewer for nih dod ada aha ukdiabetes and the italian ministry of health her contributions have been published in high impact journals journal of clinical investigation nejm nature medicine science translational medicine journal of biological chemistry diabetes kidney international and the journal of the american society of nephrology among others steven r gerst md mba mph che senior vice president and chief medical officer mzi healthcare vice president of medical affairs medcurrent corporation health informatics board member professor bryan university dr steven gerst is a graduate of the columbia university college of physicians and surgeons md columbia college ba columbia school of public health – health administration mph and the goizueta school of business at emory university mba he is a diplomat in the american college of healthcare executives and has been working on completing a doctorate in business administration and a masters in taxation he holds finra series   and  licenses for private placements dr steven gerst is also dean emeritus of the masters of science program in applied health informatics at bryan university los angeles sacramento toronto and phoenix where he serves on the board of advisors and teaches on the faculty httpbryanuniversityeduadvisoryboardmembers dr gerst also serves as an adjunct professor of biomedical informatics at nova southeastern university college of osteopathic medicine dr steven gerst is formerly senior consultant and regional medical director for what is now pricewaterhousecoopers llp he was president of columbiahca’s ppo division nationally under florida’s current governor rick scott and vice president of the corporation nysehca prior to that he was assistant vice president of crawford  company atlanta nysecrda and crdb the world’s largest independent claims management company with more than  offices in  countries at crawford  company he built the first nationwide ppo for aig boeing and other crawford clients he began his career with what is now premier inc ipo recently filed serving  member and owner hospitals where he built hmos ppos and ran the utilization management consulting division he is a licensed healthcare investment banker with stillpoint capital tampa fl and provides healthcare management consulting services to a variety of clients throughout the nation internationally focused on managed medical programs including health maintenance organizations preferred provider organizations management service organizations accountable care organizations provider sponsored networks health systems payors software companies and medical device companies most recently dr gerst worked with the broward health system memorial health system and jackson memorial health system on the florida statewide itn medicaid project valued at approximately  million per year in hospital revenues covering approximately  medicaid patients in dade and broward counties prior to this  he was involved in the merger and acquisition of  hmo’s including hip of greater new york’s florida division  million and healthnet’s foundation health plan  million to create vista health plan the largest hmo in south florida  which was then sold to coventry health plan and recently acquired by aetna for  billion pablo a guzman md facc acting chief medical officer variant pharmaceuticals dr guzman received his bachelors degree in biology in  from st peters college in jersey city his medical degree from the university of puerto rico school of medicine in  and his interventional cardiology fellowship at the johns hopkins hospital in baltimore in  where then he joined the staff for the next  years his duties included patient care teaching and both clinical and basic science research dr guzman became the assistant director of the cardiac catheterization lab and codirector of the permanent pacemaker lab at the johns hopkins hospital and also codirector of the cardiac catheterization lab at baltimore city hospital he has over  articles in peer reviewed journals and many abstracts some of them presented in national meetings including the american heart association and the american college of cardiology while at hopkins dr guzman became a fellow of the american heart association council on clinical cardiology a member of the north american society of pacing and electrophysiology and a fellow of the american college of cardiology dr guzman came to south florida in  and established a private practice in cardiology in  he designed and became the director of the cardiac catheterization laboratory at boca raton community hospital now boca regional hospital and a fellow of the society for cardiac angiography and interventions he then became the associate director of the cardiac catheterization laboratory at north ridge medical center dr guzman is a past president of the caducean society of greater fort lauderdale a past chief of the department of cardiovascular and pulmonary diseases at north ridge medical center and a member of the north ridge medical center board dr guzman was a managing partner of cardiology associates of fort lauderdale and is currently a member of the broward county medical association dr guzman has been in the private practice of medicine cardiology in south florida for  years marlene haffner md mph principal and founder at orphan solutions and haffner associates llc former director of the office of orphan products development of the fda retired rear admiral in the us public health service dr haffner was the director of the office of orphan products development at the food and drug administration for  years in addition to assisting in the development of more than  products in the us she is credited with assisting in the development of programs in japan the european union australia and beyond she founded haffner associates in  in order to continue to apply her extensive experience in development of orphan products by working with small to large biotechpharmaceutical companies patient advocacy groups and government agencies dr haffner also serves as an expert advisor and board member to companies throughout the world trained as an internist and hematologist dr haffner graduated from the george washington university school of medicine and did further training at the columbia university school of medicine and the albert einstein college of medicine in new york city she received her masters of public health from the johns hopkins bloomberg school of public health in baltimore following her tenure at fda and prior to forming haffner associates dr haffner served as executive director global regulatory intelligence and policy for two years at amgen the largest biotech company in the world dr haffner has worked in the washington dc metropolitan area for more than  years she has seen many changes in the regulatory environment during that period of time and is both sensitive and knowledgeable about politics and the political landscape she knows “fda think” and maintains close ties with her friends and colleagues in the agency jonathan j hogan md clinical director penn glomerular disease center assistant professor of medicine at the hospital of the university of pennsylvania dr hogan is clinical director of the penn glomerular disease center and assistant professor of medicine division of nephrology at the hospital of the university of pennsylvania in philadelphia he received his medical education at the university of pennsylvania school of medicine in philadelphia followed by a residency in internal medicine at the hospital of the university of pennsylvania and nephrology fellowship at new yorkpresbyteriancolumbia university medical center he then completed a fellowship in glomerular diseases at the columbia university glomerular center his clinical expertise includes glomerular diseases kidney disease in cancer patients vasculitis lupus nephritis nephrotic syndrome and proteinuria dr hogan has published more than  papers in peer reviewed medical journals dr hogan is a member of the american society of nephrology the cure glomerulopathy network and nephcure kidney international ronald j hogg mb chb dch retired pediatric nephrologist director southwest pediatric nephrology study group former chief division of pediatric nephrology baylor scott  white health temple texas former professor of pediatrics texas am health science center college of medicine temple texas dr hogg received his medical education at liverpool university medical school in liverpool england he obtained his medical degree in  and then completed  years as a resident in medicine surgery and pediatrics in england before moving to canada in  he completed his pediatric residency and a clinical pediatric nephrology fellowship at the hospital for sick children in toronto canada in  he then moved to texas where he completed a research nephrology fellowship in the department of internal medicine at the university of texas southwestern medical school utswms in dallas texas in  he then joined the faculty at utswms in the departments of pediatrics and internal medicine and subsequently was named head of the division of pediatric nephrology at utswms and children’s medical center in dallas in  he was engaged in basic renal physiology research as well as developing the pediatric dialysis and transplant program over the next  years but in  turned his attention to the development of multicenter clinical trials and formed the southwest pediatric nephrology study group this became his primary area of research activity and has remained so over the next  years dr hogg left utswms in  after being recruited to head up the pediatric department at baylor university medical center he subsequently held positions as chief of pediatric nephrology at medical city dallas hospital st joseph’s hospital in phoenix az and scott  white health care in temple texas he was also professor of pediatrics at texas am health science center college of medicine temple texas with this last position dr hogg retired from clinical practice in  but has continued with his research activities he is a member of the american society of nephrology dr hogg was the pediatric nephrologist on the original kdoqi board and an author on the initial publications describing the kdoq recommendations for patients with ckd he was also a founding member of the kd improving global outcomes kdigo board other past positions include membership on the alport syndrome foundation medical advisory board chairman of the national kidney foundation of north texas board of directors president of the national kidney foundation of north texas medical advisory board and a member of the niddk experienced reviewer reserve  dr hogg has made substantial contributions to the medicalscientific literature with well over  publications including original communications book chapters and invited reviews he has received many nih grants primarily funding the clinical trials that he has led these trials have evaluated various treatment options for children and adults with a variety of renal diseases with the most recent studies being focused on focal segmental glomerulosclerosis and iga nephropathy his other areas of interest include acute nephritic syndrome alport syndrome chronic kidney disease hematuria hypertension nephrotic syndrome nocturnal enuresis and proteinuria dr hogg is also a frequent reviewer for many nephrology journals about variant variant is a specialty pharmaceutical company that leverages advanced proprietary technologies to develop and commercialize bestinclass prescription drug therapies that optimize patient outcomes learn more pipeline  variant pharmaceuticals inc variant pharmaceuticals inc home pipeline pipeline variant invests in developing specialty pharmaceutical products that improve health outcomes and quality of life for patients with rare diseases current pipeline  initial focus is on fsgs and as our evolving product pipeline is targeted to the  billion orphan drug market our lead orphan drug candidate is hydroxypropyl beta cyclodextrin hpβcd for chronic treatment of two orphan indications var  focal segmental glomerulosclerosis fsgs and var  alport syndrome as both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids contributing to impaired kidney function ultimately leading to dialysis andor kidney transplantation hpβcd entraps and removes lipids that can cause injury to the kidneys and it is expected to delay progression of disease and prevent the need for dialysis andor transplantation in patients with fsgs and as additional orphan indications for hpβcd are under review for near term development our longerterm plans include potential development of hpβcd for prevention of diabetic kidney disease var  overview  variant pharmaceuticals inc variant pharmaceuticals inc restoring health transforming lives through innovation home about about overview variant is an emerging specialty pharmaceutical company leveraging advanced proprietary technologies to develop bestinclass drugs for patients with rare diseases our accomplished leadership team each with more than  years of demonstrated success in the biopharmaceutical and medical industries focuses on assuring that our development efforts serve the needs of all our stakeholders patients health care providers payors and our investors our evolving product pipeline is targeted to the  billion orphan drug market our lead orphan drug candidate is hydroxypropyl beta cyclodextrin hpβcd for chronic treatment of two orphan indications var  focal segmental glomerulosclerosis fsgs and var  alport syndrome as both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids contributing to impaired kidney function ultimately leading to dialysis andor kidney transplantation hpβcd entraps and removes lipids that can cause injury to the kidneys and it is expected to delay progression of disease and prevent the need for dialysis andor transplantation in patients with fsgs and as additional orphan indications for hpβcd are under review for near term development our longerterm plans include potential development of hpβcd for prevention of diabetic kidney disease var  about variant variant is a specialty pharmaceutical company that leverages advanced proprietary technologies to develop and commercialize bestinclass prescription drug therapies that optimize patient outcomes learn more home home about key facts and history board of directors  management acquisition faqs corporate governance us healthcare compliance program us assistance programs supplier diversity locations contact us operational expertise valeant united states valeant europe and the middle east valeant latin america valeant asia pacific and africa valeant canada responsibility conflict minerals statement california transparency in supply chains act of  safety data sheets investors careers benefits testimonials valeant businesses follow us us locations patients trusted expertise in  prescription brands  consumer brands branded generics special programs patient assistance program unrestricted educational grants read more what we do download resources product informationsafety data sheets regional information asia pacific and africa  canada  europe and middle east  latin america  united states research  development valeant pipeline read more news  stock ampampampampampampampampampampampampampampampampltpampampampampampampampampampampampampampampampampgtyour browser does not support iframesampampampampampampampampampampampampampampampampltpampampampampampampampampampampampampampampampampgt ampampampampampampampampampampampampampampampampltpampampampampampampampampampampampampampampampampgtyour browser does not support iframesampampampampampampampampampampampampampampampampltpampampampampampampampampampampampampampampampampgt about valeant valeant pharmaceuticals international inc is a multinational specialty pharmaceutical company that develops and markets prescription and nonprescription pharmaceutical products that make a meaningful difference in patients lives the company’s growth strategy is to acquire develop and commercialize new products through strategic partnerships and strategically expand its pipeline by adding new compounds or products through product or company acquisitions headquartered in laval quebec valeant has approximately  employees worldwide and is listed on both the new york stock and toronto stock exchanges under the symbol vrx copyright   valeant all rights reserved privacy policy legal notice sitemap bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version variant pharmaceuticals inc private company information  bloomberg july    am et pharmaceuticals company overview of variant pharmaceuticals inc snapshot people company overview variant pharmaceuticals inc operates as a specialty pharmaceutical company which develops and commercializes prescription pharmaceutical products the company focuses on developing products for the treatment of men’s health as well as for other markets where current therapies are suboptimal and underdeveloped it offers var  an oral formulation of native testosterone to treat male hypogonadism and var  that minimizes and prevents kidney cell damage and improves focal segmental glomerulosclerosis prognosis variant pharmaceuticals inc has a strategic alliance with gw laboratories inc the company was incorporated in  and is based in weston florida  north commerce parkwaysuite weston fl united statesfounded in  phone  wwwvariantpharmacom key executives for variant pharmaceuticals inc mr stephen c glover cofounder chief executive officer and director age  mr shawn m titcomb cofounder and chairman mr peter wolfe acting vice president of finance dr pablo guzman acting chief medical officer and member of scientific advisory board ms melda uzbil vice president of corporate development compensation as of fiscal year  variant pharmaceuticals inc key developments jules musing joins variant pharmaceuticals board of directors oct   variant pharmaceuticals inc announced that its board of directors has appointed jules musing former senior executive at johnson  johnson as a director of the board mr musing in the course of his year career has been responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products as well as creation of strategic alliances and partnerships on a global basis under his leadership numerous multimillion dollar deals were executed with pharmaceutical and biotechnology companies worldwide he has been president of johnson  johnson companies in the us and europe and he was on the board of johnson  johnson companies in germany france italy and the uk variant pharmaceuticals inc presents at noblecon the th annual emerging growth investor conference jan  am jan   variant pharmaceuticals inc presents at noblecon the th annual emerging growth investor conference jan  am venue club med sandpiper bay port st lucie florida united states variant pharmaceuticals enters worldwide exclusive license and development agreement with lf research dec   variant pharmaceuticals reported a worldwide exclusive license and development agreement with lf research to advance development of variants lead product var  in a release the company noted that var  has potential for treating multiple indications associated with the damaging effects of cellular accumulation of cholesterol and lipids on the kidney including focal segmental glomerulosclerosis fsgs a rare disease affecting up to  people in the united states similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target private placement january    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact variant pharmaceuticals inc please visit wwwvariantpharmacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close variant pharmaceuticals inc credit report products contacts florida search variant pharmaceuticals inc company number p status active fei number company type domestic for profit home state fl last activity date not available date of incorporation  principal address  yamato road suite  boca raton  mailing address  yamato road suite  boca raton fl  variant pharmaceuticals inc principals director titcomb shawn m address  yamato road suite  boca raton fl  director glover stephen c address  yamato road suite  boca raton fl  director pronk nico p address  yamato road suite  boca raton fl  registered agent agent name titcomb shawn p agent address  yamato road suite  boca raton fl  variant pharmaceuticals inc events  articles of correction fileddate  description variant pharmaceuticals inc has been set up  in state fl the current status of the business is active the variant pharmaceuticals inc principal adress is  yamato road suite  boca raton  meanwhile you can send your letters to  yamato road suite  boca raton fl  the companys registered agent is titcomb shawn  yamato road suite  boca raton fl  the companys management are director  titcomb shawn m director  glover stephen c director  pronk nico p the last significant event in the company history is articles of correction which is dated by  this decision is take in action on unknown comprehensive report about this company view sample similar companies variant publications llc variant services inc variant technologies inc variant trading institutional group inc variant trend solutions variant usa llc   variant pharmaceuticals inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       variant pharmaceuticals inc print preview export bookmark share with colleague general information  location weston fla  region southeast  country us  business category renal endocrinemetabolic  year founded   website httpwwwvariantpharmacom  lead product status preclinical  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft